Jim Cramer Says “Look, in the End, There’s Eli Lilly and There’s Everybody Else”

Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently shared thoughts on. Cramer mentioned the stock during the episode and commented:

“I do believe that there are very few biotechs that I really want to buy right now because they’re so picked over. Look, in the end, there’s Eli Lilly and there’s everybody else.”

Pixabay/Public Domain

Eli Lilly and Company (NYSE:LLY) develops medicines for diabetes, obesity, cancer, autoimmune disorders, and neurological conditions. Cramer discussed the stock during the October 30 episode and highlighted its solid GLP-1 revenue, as he said:

“Or how about the drug companies? Holy cow, remember them? They used to be big and important, weren’t they? Eli Lilly reported this morning, and their GLP-1 complex, you know, the weight loss diabetes thing, made a billion dollars more than Wall Street expected. That’s tech-like. When I first saw it, I was thinking, okay, the market won’t care. Big yawner. We own Lilly for the trust, we believe in it, but we feel like we’re dopes lately.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.

View Comments